H.R. 9682 · 119th Congress (2025–2027)
Cure Hepatitis C Act of 2026
This bill establishes programs and requirements to provide free medications to treat hepatitis C in certain high-risk or vulnerable populations. It also establishes grants and other resources to support testing and treatment for hepatitis C. The bill provides funding for FY2027 to implement these provisions.
The Department of Health and Human Services (HHS) must enter into a five-year purchasing contract with manufacturers of drugs that treat hepatitis C so that eligible individuals may receive the drugs without cost-sharing. Eligible individuals are those diagnosed with hepatitis C who are (1) enrolled in Medicaid or the Children’s Health Insurance Program (CHIP), (2) confined to federal, state, or local correctional facilities (or were released and began treatment there), (3) uninsured, or (4) receiving health care through the Indian Health Service.
State Medicaid and CHIP programs and state and local correctional facilities may opt into the program; participation is mandatory for federal correctional facilities and the Indian Health Service.
HHS must award grants to certain entities, including states, public health organizations, and correctional facilities, to support the coordination and provision of screening, treatment, and supportive services for the affected populations.
The bill also allows Medicare beneficiaries to receive hepatitis C drugs without cost-sharing from 2028-2032.
Show official title
To require the Secretary of Health and Human Services to carry out activities to eliminate hepatitis C virus in the United States.
Referred to committee
Latest actionReferred to committee
This bill’s path
This is H.R. 9682’s recorded path, not a universal congressional workflow.
How bills become lawAll actionsIntroduced
Passed House
Passed Senate
Sent to President
Signed into law
- Sponsor
- Rep. Mariannette Miller-Meeks (R-IA-1)
- Cosponsors
6 cosponsors
3 original · 3 later
1 R · 5 D
- Rep. Don Bacon (R-NE-2)· Original · Jul 14, 2026
- Rep. Diana DeGette (D-CO-1)· Original · Jul 14, 2026
- Rep. Henry C. "Hank" Johnson, Jr. (D-GA-4)· Original · Jul 14, 2026
- Rep. Josh Gottheimer (D-NJ-5)· Later · Aug 10, 2026
- Rep. Emanuel Cleaver (D-MO-5)· Later · Sep 24, 2026
- Rep. Jake Auchincloss (D-MA-4)· Later · Oct 5, 2026
- Policy area
- Health
On this page
Timeline
i
In chronological order. Major procedural acts are shown in full. Committee work and ordinary amendments fold in place where they happened, so they do not jump the sequence or stretch the timeline.
Introduced in House
Document: Introduced in House
Sources
- Congress.gov actionIntro-H
- Library of Congress
- Latest
Referred to committee
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Natural Resources, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sources
- Congress.gov action
- House floor actions
Committees
Text & titles
i
Each distinct name Congress.gov recorded, once. Official, short, display, and popular titles stay distinct when the wording differs. The same wording is not repeated for every text version.
| Version | Date | Links |
|---|---|---|
| Introduced in House |
Titles (2)
To require the Secretary of Health and Human Services to carry out activities to eliminate hepatitis C virus in the United States.
Official title · Introduced in House
Cure Hepatitis C Act of 2026
Display title, Short title · Introduced in House